Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: A

Drug products: ADT, Amitriptylin "DAK", Amitriptylin Abcur, Amitriptylin Orifarm, Amitriptyline Hydrochloride, Amitriptyline Strides, Laroxyl, Saroten®, Triptyl, Tryptizol, Tryptizol®

ATC code: N06AA09

Substances: amitriptyline, amitriptyline chloride


The efficacy of amitriptyline in treatment of depression is similar in men and women. Evidence of sex differences in the effect in migraine is unclear. Clinical studies on sex differences regarding the effects of amitriptyline in treatment of bipolar disorder or neuropathic pain are lacking.

Amitriptyline is associated with QT-prolongation on ECG and thus a risk of potentially fatal arrhythmia of the type Torsade de Pointes ventricular tachycardia. No difference in risk between men and women has been shown but female sex is a known risk factor for Torsade de Pointes ventricular tachycardia.

Additional information

Depression is almost twice as common in women as in men [1]. Women have an earlier age of onset and increased duration of depressive episodes. Differences in neurobiology [2, 3], hormones, inflammatory markers, diagnostic tools, or health seeking behavior [4, 5] may be of importance.  Although depression is more prevalent in women, most preclinical studies on depression have used  male animals [2].

Women are two to three times more likely to suffer from an anxiety disorder [1]. Sex differences in symptomatology and comorbidity  may be due to genetic, hormonal, neurodevelopmental, environmental, and neurobiological factors [6].Amitriptyline is also used in treatment of neuropathic pain, which is more common in women than in men [7].

Pharmacokinetics and dosing

Several studies have shown similar plasma levels of amitriptyline in depressed men and women receiving standard routine doses [8-13]. However, women >50 years old had higher total tricyclic antidepressants (TCA) plasma levels (amitriptyline + its active metabolite nortriptyline) per milligram of drug administrated than age-matched men [10].

The mean ratio of nortriptyline/amitriptyline was similar in depressed men and women (26 men, 39 women) receiving 50-200 mg/day for >3 weeks [14]. Another even smaller study in chronic pain patients (8 men, 11 women) found a higher mean nortriptyline/amitriptyline ratio in women after receiving amitriptyline 75 mg /day for 6 weeks [11]. The authors speculate that this indicates a sex difference in amitriptyline metabolism [11]. Amitriptyline is metabolized by CYP2D6 [15]. No sex difference in general has been reported for this enzyme although the activity increases during pregnancy [16, 17].


A meta-analysis consisting of three RCTs of amitriptyline and 27 RCTs of imipramine (in total 1555 men, 2331 women) showed no sex differences in TCA efficacy in major depression [18].

The effect of TCAs and MAO inhibitors in patients with major depression, generalized anxiety, or panic disorder were evaluated with pooled data from five double-blind studies (in total 40 men, 111 women, on amitriptyline 21 men, 25 women). The studies lasted between 4-6 weeks. Men with panic attacks responded better to TCAs such as amitriptyline than to MAOIs, while women with panic attacks responded better to MAOIs than to TCAs [19].

The efficacy of amitriptyline as migraine prophylaxis in adults has been evaluated in a double-blind, randomized, 3-armed crossover study (8 men, 22 women). Patients initially received placebo followed by a 4-week period with amitriptyline 40 mg, propranolol 25 mg or placebo. Amitriptyline reduced the severity, frequency, and duration of headache attacks. Amitriptyline response was associated with female sex [20, 21]. Since the study included a low number of men, there is insufficient evidence to draw any conclusions about the effect in men.

No studies with a clinically relevant sex-analysis regarding the effects of amitriptyline in neuropathic pain have been found.

Adverse effects

Amitriptyline has been associated with prolonged QT-interval and a risk of Torsade de Pointes ventricular tachycardia [22].  Risk factors of drug-induced ventricular arrhythmias are female sex, hypokalemia, bradycardia, and base line QT-prolongation [23].

A systematic review reports that men have a six-fold higher risk of amitriptyline-associated sexual dysfunction than women. Amitriptyline was associated with a detoriation of sexual function in men, while a trend of improvement was observed in women [24].

The risk of venous thromboembolism (VTE) in antidepressant users was evaluated in a nested case-control study based on UK register data (in total 1346 men, 2521 women). Users of amitriptyline had almost a 2-fold increased risk (OR 1.7) for VTE compared with non-users but no sex difference was noted. An increased risk of VTE was found among women currently using oral contraceptives (OR 2.2) or hormone replacement therapy (OR 2.2) [25].

The fracture risk in patients taking antidepressants has been evaluated in a Danish case-control study (cases: 60 107 men, 64548 women; controls: 180 321 men, 193 641 women). For TCAs, an increase in fracture risk was only seen with amitriptyline, and the risk was higher with increased use (DDD/day), however no sex-stratified data was shown [26].

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information

Drug utilization of ten commonly prescribed antidepressants during the period 2009-2014 in Sweden, Denmark, Germany, and Spain were analyzed in a large register study (in total 4 833 774 initiators included). Women comprised the majority of initiators for all antidepressants studied. In Sweden, 69% of the initiators on amitriptyline were women [27].

Adherence to amitriptyline, nortriptyline or imipramine in patients with pain was evaluated retrospectively by analyzing urine specimens and comparing with medication lists reported by the health care provider in a U.S. study (30 910 men, 24 386 women). Women were more adherent than men (68% vs. 61%) suggesting higher compliance in women [28].

TCA intoxications have been reported to be more frequent among women, but patterns differ between populations [29,30]. Also, toxic TCA plasma concentrations (>450 mcg/dl) have been found to a higher extent in women [31].

Updated: 2022-06-13

Date of litterature search: 2021-06-18


  1. Nationella riktlinjer för vård vid depression och ångestsyndrom 2021. Socialstyrelsen [www]. Socialstyrelsen. [updated 2021-04-01, cited 2021-05-14]. länk
  2. LeGates TA, Kvarta MD, Thompson SM. Sex differences in antidepressant efficacy. Neuropsychopharmacology. 2019;44(1):140-154. PubMed
  3. Sramek JJ, Murphy MF, Cutler NR. Sex differences in the psychopharmacological treatment of depression. Dialogues Clin Neurosci. 2016;18(4):447-457. PubMed
  4. Kerber CS, Dyck MJ, Culp KR, Buckwalter K. Antidepressant treatment of depression in rural nursing home residents. Issues Ment Health Nurs. 2008;29(9):959-73. PubMed
  5. Labaka A, Goñi-Balentziaga O, Lebeña A, Pérez-Tejada J. Biological Sex Differences in Depression: A Systematic Review. Biol Res Nurs. 2018;20(4):383-392. PubMed
  6. Jalnapurkar I, Allen M, Pigott T. Sex Differences in Anxiety Disorders: A Review. J Psychiatr Depress Anxiety. 2018;4(1):2-9.
  7. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380-387. PubMed
  8. Vandel S, Vandel B, Sandoz M, Allers G, Bechtel P, Volmat R. Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline. Eur J Clin Pharmacol. 1978;14:185-90. PubMed
  9. Jungkunz G, Kuss HJ. On the relationship of nortriptyline: amitriptyline ratio to clinical improvement of amitriptyline treated depressive patients. Pharmakopsychiatr Neuropsychopharmakol. 1980;13:111-6. PubMed
  10. Preskorn SH, Mac DS. Plasma levels of amitriptyline: effect of age and sex. J Clin Psychiatry. 1985;46:276-7. PubMed
  11. Edelbroek PM, Linssen AC, Zitman FG, Rooymans HG, de Wolff FA. Analgesic and antidepressive effects of low-dose amitriptyline in relation to its metabolism in patients with chronic pain. Clin Pharmacol Ther. 1986;39:156-62. PubMed
  12. Rudorfer MV, Robins E. Amitriptyline overdose: clinical effects on tricyclic antidepressant plasma levels. J Clin Psychiatry. 1982;43(11):457-60. PubMed
  13. Unterecker S, Riederer P, Proft F, Maloney J, Deckert J, Pfuhlmann B. Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions. J Neural Transm (Vienna). 2013;120(8):1237-46. PubMed
  14. Ziegler VE, Biggs JT. Tricyclic plasma levels Effect of age, race, sex, and smoking. JAMA. 1977;238:2167-9. PubMed
  15. Martindale: The Complete Drug Reference. Pharmaceutical Press.
  16. Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res. 2007;55:81-95. PubMed
  17. Nicolson TJ, Mellor HR, Roberts RR. Gender differences in drug toxicity. Trends Pharmacol Sci. 2010;31:108-14. PubMed
  18. Wohlfarth T, Storosum JG, Elferink AJ, van Zwieten BJ, Fouwels A, van den Brink W. Response to tricyclic antidepressants: independent of gender?. Am J Psychiatry. 2004;161(2):370-2. PubMed
  19. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res. 1986;17:87-95. PubMed
  20. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis A comparison of propranolol and amitriptyline. Arch Neurol. 1987;44:486-9. PubMed
  21. Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine Pharmacokinetic and therapeutic effects. Arch Neurol. 1993;50:825-30. PubMed
  22. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004;45:371-7. PubMed
  23. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22. PubMed
  24. Chen LW, Chen MY, Lian ZP, Lin HS, Chien CC, Yin HL et al. Amitriptyline and Sexual Function: A Systematic Review Updated for Sexual Health Practice. Am J Mens Health. 2018;12(2):370-379. PubMed
  25. Jick SS, Li L. Antidepressant drug use and risk of venous thromboembolism. Pharmacotherapy. 2008;28:144-50. PubMed
  26. Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int. 2008;82:92-101. PubMed
  27. Forns J, Pottegård A, Reinders T, Poblador-Plou B, Morros R, Brandt L et al. Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators. J Affect Disord. 2019;249:242-252. PubMed
  28. Bordson SJ, Atayee RS, Ma JD, Best BM. Tricyclic antidepressants: is your patient taking them? Observations on adherence and unreported use using prescriber-reported medication lists and urine drug testing. Pain Med. 2014;15:355-63. PubMed
  29. Güloglu C, Orak M, Ustündag M, Altunci YA. Analysis of amitriptyline overdose in emergency medicine. Emerg Med J. 2011;28:296-9. PubMed
  30. Dianat S, Zarei MR, Hassanian-Moghaddam H, Rashidi-Ranjbar N, Rahimian R, Rasouli MR. Tricyclic antidepressants intoxication in Tehran, Iran: epidemiology and associated factors. Hum Exp Toxicol. 2011;30:283-8. PubMed
  31. Billups SJ, Delate T, Dugan D. Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations. Pharmacoepidemiol Drug Saf. 2009;18:253-7. PubMed
  32. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Diana Rydberg

Approved by: Karin Schenck-Gustafsson